The Lake County Health Department (LCHD) will be providing Evusheld to Lake County residents under the FDA Emergency Use Authorization (EUA).  

Evusheld (tixagevimab co-packaged cilgavimab), a SARS CoV-2 spike protein-directed attachment inhibitor, is currently the only pre-exposure prophylaxis indicated for individuals at high-risk for complications to COVID-19. Evusheld is administered by two injections immediately given one after another. The medication will be administered at no cost for patients referred by their providers, but there will be a cost for clinic visits at LCHD. Patients with insurance will be billed, and for those who are uninsured, charges are based on a sliding scale fee schedule based on income.   

Indications for Evusheld use: 

• 12 years of age or older, AND 

• Weighs at least 40 kg (88 pounds), AND 
• Not currently infected with SARS-CoV-2, AND 
• No known recent exposure to an individual infected with SARS CoV-2, AND 
• Has moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination 

OR 

For those who vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or vaccine component(s). 

Refer your high-risk patients to LCHD by completing these steps: 

• Healthcare providers should identify and assess their patient’s eligibility for Evusheld. 
• If eligible, the provider should educate their patient about the Evusheld’s risks, benefits, contraindications, “What to expect during the visit” (see below), and provide the Evusheld Fact Sheet.
• Document in your patient’s record the recommendation for Evusheld, indicate patient was counseled on risks/benefits, and provided the Evusheld Fact Sheet. 

• Contact the LCHD’s Sexually Transmitted Illness (STI) Program Coordinator (ph.# 847-377-8761) to set up the appointment. Please note Evusheld is being administered to patients in the community through our STI program. 
• Fax a letter of necessity for Evusheld and patient’s records to the STI program (Fax # 847-360-2920) prior to the appointment. See LCHD’s Evusheld Information for Community Healthcare Providers for details. 

What to expect during the visit 

The patient will be instructed to go to the Health Department STI clinic. At the clinic, the healthcare provider will review all faxed documents, review the Evusheld Fact Sheet, and answer any remaining questions. The provider will administer the injections. The patient will be monitored for one hour for adverse events. Patients will be instructed to call 911 if they have a severe adverse reaction after they leave. The referring healthcare provider or an emergency department should address any adverse events that occur after the patient leaves the STI clinic and should be reported to the appropriate authorities (see Evusheld Fact Sheet for Healthcare Providers). 

Please contact LCHD’s STI coordinator, Valerie Johansen, for any scheduling and any questions, (ph.# 847-377-8761, fax# 847-360-2920). The STI Program is located at the Belvidere Medical Building, 2400 Belvidere Road, Waukegan, IL 60085. For more details, please see the LCHD’s Evusheld Information for Community Healthcare Providers.